Document is current
Any future updates will be listed below
-
Authors
Mao, Shiqi
Yang, Shuo
Liu, Xinyu
Li, Xingya
Wang, Qiming
Zhang, Yiping
Chen, Jianhua
Wang, Yan
Gao, Guanghui
Wu, Fengying
Jiang, Tao
Zhang, Jiao
Yang, Ying
Lin, Xiang
Zhu, Xiaoyu
Zhou, Caicun
Ren, Shengxiang
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02535507 at ClinicalTrials.govnct02834936 at ClinicalTrials.govDocuments that mention this clinical trial
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials
https://doi.org/10.1186/s40164-023-00417-y
Documents that mention this clinical trial
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials
https://doi.org/10.1186/s40164-023-00417-y
Activating HER2 mutations as emerging targets in multiple solid cancers
https://doi.org/10.1136/esmoopen-2017-000279
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (No.82002419, No. 81972167)
Shanghai Innovative Collaboration Project (No. 2020CXJQ02)
Shanghai Shenkang Hospital Development Center (No. SHDC12019133)
Science and Technology Commission of Shanghai Municipality (No. 21XD1423200)
Clinical Research foundation of Shanghai Pulmonary Hospital (No. FKLY20008)
- License Information
-
More Information
Article History
Received: 26 October 2022
Accepted: 18 May 2023
First Online: 9 June 2023
Declarations
:
: This study was approved by the Ethics Committee of Shanghai Pulmonary Hospital, Tongji University School of Medicine. The procedures used in this study adhere to the tenets of the Declaration of Helsinki (as revised in 2013).
: Not applicable.
: Jiao Zhang and Ying Yang are employees of Genecast Biotechnology Co., Ltd. Xiang Lin and Xiaoyu Zhu are employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd. No other disclosures were reported.
